<DOC>
	<DOCNO>NCT02264613</DOCNO>
	<brief_summary>This study evaluate anti-tumor effect ALRN-6924 patient advance solid tumor lymphomas WT TP53 .</brief_summary>
	<brief_title>ALRN-6924 Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>Open label , multi-center dose escalation ( DEP ) dose expansion ( EXP ) study design evaluate safety , tolerability , PK ( pharmacokinetics ) , PD ( pharmacodynamics ) anti-tumor effect ALRN-6924 patient advance solid tumor lymphomas wild-type ( WT ) TP53 . ALRN-6924 staple peptide design disrupt integration p53 tumor suppression protein inhibition murine double minute 2 ( MDM2 ) murine double minute X ( MDMX ) . The DEP portion study enroll adult histologically- cytologically-confirmed malignancy metastatic unresectable standard treatment ( ) available longer effective enrolled.The EXP portion study enroll distinct group patient specific solid tumor and/or lymphomas investigate clinical safety profile potential efficacy ALRN 6924 MTD OBD . PTCL select one EXP group study . Treatment patient DEP EXP phase continue study documentation disease progression , unacceptable toxicity , patient physician decision discontinue study participation make .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>Inclusion Criteria Male female patient age 18 year old , inclusive , time informed consent Histologically cytologicallyconfirmed malignancy metastatic unresectable standard measure exist longer effective ( DEP ) histologically confirm diagnosis PTCL base pathology review local institution , use recent edition WHO Classification , relapse refractory disease least one prior systemic anticancer regimen ( EXP PTCL ) WT TP53 status At least one target lesion measurable RECIST 1.1 solid tumor , IWG 2014 lymphoma ECOG ( Eastern Cooperative Oncology Group ) performance status 01 Adequate hematologic function Adequate hepatic function Acceptable coagulation profile Recovery significant toxicity previous therapy sufficient time since last dose previous therapy Previous treatment investigational agent inhibit MDM2 MDMX activity ( MDM2treated patient may eligible ) Known hypersensitivity study drug component Known untreated brain metastasis . Patients primary CNS ( central nervous system ) malignancy exclude . History coagulopathy , platelet disorder history nondrug induce thrombocytopenia History pulmonary embolism within 6 month prior first dose ALRN6924 untreated DVT ( deep vein thrombosis ) Required concurrent use anticoagulant antiplatelet medication , exception aspirin dose ≤81 mg/day , lowdose SC heparin SC lowmolecularweight heparin DVT prophylaxis , heparin flush maintain IV catheter patency Patients preexist history know cardiovascular risk Clinically significant gastrointestinal bleeding within 6 month prior first dose ALRN6924 Clinically significant thirdspace fluid accumulation Active uncontrolled infection , include HIV/AIDS Hepatitis B C Patients cancer likely Human Papilloma Virus ( HPV ) positive cervical cancer , oropharyngeal cancer anal cancer must undergo additional screening determine eligibility Known history another primary malignancy remission ≥2 year Required use medication predominantly clear hepatobiliary transporter within 48 hour study drug infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>